Pilot for The Breast Cancer Endocrine Therapy Adherence (BETA) Trial

Completed · Not applicable

Conditions studied: Breast Cancer

In brief

Pilot study to assess feasibility and patient acceptance of a text message cell phone application for patients with stage I-III, hormone receptor positive breast cancer who start adjuvant endocrine therapy.

Key facts

Study ID

NCT02256670

Run by

Yale University

People needed

100

Starts

2014-10-01

Expected to finish

2016-08-01

Last updated by the study team

2017-02-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patients with histologically confirmed stage I-III, estrogen and/or progesterone receptor positive, as defined by ASCO-CAP guidelines, invasive breast cancer for whom adjuvant hormonal therapy is indicated following standard NCCN practice guidelines
• Patients may enter the study before or within one month of starting endocrine treatment
• Patients with synchronous bilateral breast cancers are eligible if both tumors are hormone receptor positive
• Patient must be able to provide informed consent and agree to:
• Complete questionnaires according to the pre-specified study design
• Own a personal cell phone, agree to receive text messages on a monthly basis (including any costs), and share their personal cell phone number to receive text message reminder
• sign consent to allow research staff to contact their pharmacies to determine prescription refill dates

You may not qualify if…

• Patients with ductal carcinoma in situ

Where it is running

• Yale New Haven Hospital — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.